share_log

Transcode Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-3i, LP(0%),3i Management LLC(0%), etc.

Transcode Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-3i, LP(0%),3i Management LLC(0%), etc.

Transcode Therapeutics | SC 13G/A:超過5%持股股東披露文件(修正)-3i, LP(0%),3i Management LLC(0%)等
美股SEC公告 ·  2024/11/07 05:08

Moomoo AI 已提取核心訊息

Transcode Therapeutics, Inc. has been the subject of an amended filing with the U.S. Securities and Exchange Commission (SEC) on September 30, 2024. The filing, an Amendment No. 1 to Schedule 13G, indicates that the reporting persons, 3i, LP, 3i Management LLC, and Maier Joshua Tarlow, have ceased to be the beneficial owners of more than five percent of the outstanding common stock of Transcode Therapeutics. This amendment serves as an exit filing for the reporting persons, effectively updating their beneficial ownership information and amending previous disclosures. The reporting persons have confirmed that their holdings are not for the purpose of changing or influencing the control of the issuer. The principal business address for all reporting persons is listed as 2 Wooster Street, 2nd Floor, New York, NY 10013.
Transcode Therapeutics, Inc. has been the subject of an amended filing with the U.S. Securities and Exchange Commission (SEC) on September 30, 2024. The filing, an Amendment No. 1 to Schedule 13G, indicates that the reporting persons, 3i, LP, 3i Management LLC, and Maier Joshua Tarlow, have ceased to be the beneficial owners of more than five percent of the outstanding common stock of Transcode Therapeutics. This amendment serves as an exit filing for the reporting persons, effectively updating their beneficial ownership information and amending previous disclosures. The reporting persons have confirmed that their holdings are not for the purpose of changing or influencing the control of the issuer. The principal business address for all reporting persons is listed as 2 Wooster Street, 2nd Floor, New York, NY 10013.
Transcode Therapeutics, Inc.已成爲2024年9月30日與美國證券交易委員會(SEC)提交的修正文件的主題。該文件是第一項對13G表的修正,表明申報人3i、3i Management LLC和Maier Joshua Tarlow已經不再是Transcode Therapeutics的流通普通股超過5%的有益所有者。此修正文件作爲申報人的退出文件,有效更新其有益所有權信息並修訂先前的披露。申報人已確認,其持有不是爲了改變或影響發行人的控制。所有申報人的主營業務地址均列爲紐約市10013號2 Wooster Street,2樓。
Transcode Therapeutics, Inc.已成爲2024年9月30日與美國證券交易委員會(SEC)提交的修正文件的主題。該文件是第一項對13G表的修正,表明申報人3i、3i Management LLC和Maier Joshua Tarlow已經不再是Transcode Therapeutics的流通普通股超過5%的有益所有者。此修正文件作爲申報人的退出文件,有效更新其有益所有權信息並修訂先前的披露。申報人已確認,其持有不是爲了改變或影響發行人的控制。所有申報人的主營業務地址均列爲紐約市10013號2 Wooster Street,2樓。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息